SAN DIEGO--(BUSINESS WIRE)--Sept. 14, 2004--Arena Pharmaceuticals,
Inc. (NASDAQ:ARNA) announced today that Jack Lief, President and Chief
Executive Officer, is scheduled to present a corporate update at the
Merriman Curhan Ford & Co. Investor Summit 2004 on Monday, September
20, 2004. The presentation is scheduled to take place at 2:...
SAN DIEGO, Aug. 13 /PRNewswire/ -- Arena Pharmaceuticals (Nasdaq: ARNA)
will present a corporate update at the following forum:
What: Arena Pharmaceuticals will give a presentation at Informed
Investors Healthcare Virtual Stocks Forum
Robin R. Young, CFA, Managing Director, Research Healthpoint
...
SAN DIEGO, Aug 10, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today the achievement of a $3 million milestone from
Merck & Co., Inc. for assay development under their cardiovascular
collaboration.
In October 2002, Arena and Merck entered into a collaboration focused on a
group...
SAN DIEGO, Jul 26, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it has initiated a Phase 1b clinical trial
of APD356, its 5-HT2C selective, lead anti-obesity compound. The purpose of
this Phase 1b study is to evaluate safety at steady state drug levels during
14-day repeated daily...
SAN DIEGO, Jul 20, 2004 (PRNewswire-FirstCall via COMTEX) -- Arena Pharmaceuticals, Inc. today announced that the company will release second quarter 2004 financial results after the NASDAQ National Market closes on Tuesday, July 20, 2004. Arena also announced today that Jack Lief, President and Chief Executive Officer of Arena, will host a conf...
SAN DIEGO, July 20 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported financial results for the second quarter and six
months ended June 30, 2004.
Total revenues in the second quarter of 2004 were $1.4 million, compared
to $3.0 million in the second quarter of 2003. Total revenues for the six
...
SAN DIEGO, Jul 14, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today results from a Phase 1a, single-dose clinical
trial of the company's novel anti-obesity compound, APD356. APD356 is an
orally administered small molecule that is a selective 5-HT2C serotonin
receptor agonist. The 5-HT2C r...
SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that the company will release second quarter
2004 financial results after the NASDAQ National Market closes on Tuesday,
July 20, 2004. Arena also announced today that Jack Lief, President and Chief
Executive Officer of Arena, will host...
SAN DIEGO, June 14 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that Jack Lief, President and Chief Executive
Officer, is scheduled to present a corporate update at the Needham & Company
Third Annual Biotechnology Conference on Thursday, June 17, 2004. The
presentation is scheduled to take pla...
SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that Dominic Behan, Vice President, Research
and co-founder of Arena, is scheduled to present a corporate update at the
Rodman & Renshaw Techvest Global Healthcare Conference on Wednesday,
May 12, 2004. The presentation is scheduled...
SAN DIEGO, Apr 26, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that Jack Lief, President and Chief Executive
Officer, is scheduled to present a corporate update at the CIBC World Markets
Annual Biotechnology and Specialty Pharmaceuticals Conference on Wednesday,
April 28, 2004. The pr...
SAN DIEGO, April 20 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported financial results for the first quarter of 2004.
Total revenues in the first quarter of 2004 were $5.8 million, compared to
$5.4 million in the first quarter of 2003. Arena reported a net loss
allocable to common stockholde...
SAN DIEGO--(BUSINESS WIRE)--April 13, 2004--Arena Pharmaceuticals,
Inc. (NASDAQ:ARNA) today announced that the company will release first
quarter 2004 financial results after the NASDAQ National Market closes
on Tuesday, April 20, 2004. Arena also announced today that Jack Lief,
President and Chief Executive Officer of Arena, will host a...
SAN DIEGO, Mar 17, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced the appointment of William R. Shanahan, Jr.,
M.D., J.D. as Vice President, Chief Medical Officer, effective March 29, 2004,
to head its clinical development operations.
"As we transition from discovery research and...
SAN DIEGO, Feb 25, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced the achievement of a $4 million milestone
related to animal testing of small molecules that act upon selected G
protein-coupled receptors (GPCRs), which may represent novel targets for
cardiovascular disease. Arena and Mer...
SAN DIEGO, Feb 24, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it has initiated a Phase 1 clinical trial
in the United Kingdom for APD356, its lead anti-obesity compound. This
double-blind, placebo-controlled, single-dose, dose-escalation trial is
planned to enroll 54 healthy, ove...
SAN DIEGO, Jan. 20 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported revenues of $1.6 million for the quarter ended
December 31, 2003, compared to fourth quarter 2002 revenues of $6.4 million,
and $12.8 million in revenues for the full year ended December 31, 2003,
compared to $19.4 million in revenues f...
SAN DIEGO, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals,
Inc. (Nasdaq: ARNA) today announced that it will release its financial results
for the fourth quarter and full year of 2003 after the NASDAQ National Market
closes on Tuesday, January 20, 2004, and will host both a telephone and
Internet fourth quarter conference ...
SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced the resignation of its Chief Financial Officer,
Joseph F. Mooney. Arena's Vice President, Finance, Robert E. Hoffman, will
continue to serve as its chief accounting officer.
Jack Lief, Arena's President and Chief Executive O...
SAN DIEGO, Dec. 24 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that it has completed the private placement of
$35 million of Series B-1 Convertible Preferred Stock to two institutional
investors. Arena expects to use the net proceeds from the financing for
working capital and general corporate purposes....
